FDA panel to discuss GSK’s malaria candidate

FDA's Antimicrobial Drugs Advisory Committee will meet on July 12 to discuss an NDA for single-dose 150 mg tafenoquine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to prevent relapse of Plasmodium vivax malaria. Tafenoquine, an 8-aminoquinoline derivative, has breakthrough therapy designation from FDA...